Claims for Patent: 6,376,502

Summary for Patent: 6,376,502

Title:	Osteoporosis compounds
Abstract:	This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
Inventor(s):	Cameron; Kimberly O. (East Lyme, CT), Lefker; Bruce A. (Gales Ferry, CT), Rosati; Robert L. (Stonington, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	09/511,128
Patent Claims:	1. A compound of Formula I ##STR10## a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein: B is N; L is n-propylenyl-X--, wherein X is furanyl, thienyl, thiazolyl or tetrahydrofuranyl, said X being optionally mono-, di- or tri-substituted on aromatic carbon independently with one to three chloro, fluoro, methoxy, difluoromethoxy, trifluoromethoxy, trifluoromethyl or methyl; R is carboxyl, (C.sub.1 -C.sub.6)alkoxycarbonyl, tetrazolyl, 5-oxo-1,2,4-thiadiazolyl; 5-oxo-1,2,4-oxadiazolyl, (C.sub.1 -C.sub.4)alkylsulfonylcarbamoyl or phenylsulfonylcarbamoyl; R.sup.1 is H, methyl, ethyl or propyl; R.sup.2 is H or (C.sub.2 -C.sub.5)alkanoyl; R.sup.3 is independently H, fluoro or methyl; R.sup.4 is H, (C.sub.1 -C.sub.7)alkyl, or R.sup.4 and R.sup.1 are taken together to form a 5-9 membered carbocyclic ring, said alkyl being optionally monounsaturated and optionally mono-, di- or tri-substituted independently with one to three fluoro, chloro, methoxy, difluoromethoxy, trifluoromethoxy, trifluoromethyl or methyl; R.sup.5 is (C.sub.1 -C.sub.6)alkylsulfonyl, (C.sub.3 -C.sub.7)cycloalkylsulfonyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.6)alkylsulfonyl, (C.sub.1 -C.sub.6)alkylcarbonyl, (C.sub.3 -C.sub.7)cycloalkylcarbonyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.6)alkylcarbonyl, G-sulfonyl or G-carbonyl, said (C.sub.1 -C.sub.6)alkylsulfonyl, (C.sub.3 -C.sub.7)cycloalkylsulfonyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.6)alkylsulfonyl, (C.sub.1 -C.sub.6)alkylcarbonyl, (C.sub.3 -C.sub.7)cycloalkylcarbonyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.6)alkylcarbonyl optionally mono-, di- or tri-substituted on carbon independently with hydroxy, fluoro, chloro, methoxy, difluoromethoxy, trifluoromethoxy, trifluoromethyl or methyl; Z is methylene, ethylene, propylene or ethenylene; G is Ar, Ar.sup.1 --V--Ar.sup.2, Ar--(C.sub.1 -C.sub.6)alkylene, Ar--CONH--(C.sub.1 -C.sub.6)alkylene, R.sup.12 R.sup.13 -amino, oxy(C.sub.1 -C.sub.6)alkylene, amino substituted with Ar, or amino substituted with Ar(C.sub.1 -C.sub.4)alkylene and R.sup.11, wherein R.sup.11 is H or (C.sub.1 -C.sub.8)alkyl, R.sup.12 and R.sup.13 may be taken separately and are independently selected from H and (C.sub.1 -C.sub.8)alkyl, or R.sup.12 and R.sup.13 are taken together with the nitrogen atom to which they are attached to form a five- or six-membered azacycloalkyl, said azacycloalkyl optionally containing an oxygen atom and optionally substituted with up to two oxo, hydroxy, (C.sub.1 -C.sub.4)alkyl, fluoro or chloro; Ar is a partially saturated or fully unsaturated five to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused independently partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, or a tricyclic ring consisting of three fused independently partially saturated, fully saturated or fully unsaturated five or six membered rings, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, said partially or fully saturated ring, bicyclic ring or tricyclic ring optionally having one or two oxo groups substituted on carbon or one or two oxo groups substituted on sulfur; or Ar is a fully saturated five to seven membered ring having one or two heteroatoms selected independently from oxygen, sulfur and nitrogen; Ar.sup.1 and Ar.sup.2 are each independently a partially saturated, fully saturated or fully unsaturated five to eight membered ring optionally having one to four heteroatoms selected independently from oxygen, sulfur and nitrogen, or a bicyclic ring consisting of two fused independently partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, or a tricyclic ring consisting of three fused independently partially saturated, fully saturated or fully unsaturated five or six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen, said partially or fully saturated ring, bicyclic ring or tricyclic ring optionally having one or two oxo groups substituted on carbon or one or two oxo groups substituted on sulfur; said Ar, Ar.sup.1 and Ar.sup.2 moieties are optionally substituted on carbon or nitrogen, on one ring if the moiety is monocyclic, on one or both rings if the moiety is bicyclic, or on one, two or three rings if the moiety is tricyclic, with up to three substituents per moiety, independently selected from R.sup.14, R.sup.15 and R.sup.16 wherein R.sup.14, R.sup.15 and R.sup.16 are independently hydroxy, nitro, halo, carboxy, (C.sub.1 -C.sub.7)alkoxy, (C.sub.1 -C.sub.4)alkoxy(C.sub.1 -C.sub.4)alkyl, (C.sub.1 -C.sub.4)alkoxycarbonyl, (C.sub.1 -C.sub.7)alkyl, (C.sub.2 -C.sub.7)alkenyl, (C.sub.2 -C.sub.7)alkynyl, (C.sub.3 -C.sub.7)cycloalkyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.4)alkyl, (C.sub.3 -C.sub.7)cycloalkyl(C.sub.1 -C.sub.4)alkanoyl, formyl, (C.sub.1 -C.sub.8)alkanoyl, (C.sub.1 -C.sub.6)alkanoyl(C.sub.1 -C.sub.6)alkyl, (C.sub.1 -C.sub.4)alkanoylamino, (C.sub.1 -C.sub.4)alkoxycarbonylamino, hydroxysulfonyl, aminocarbonylamino or mono-N-, di-N,N-, di-N,N'- or tri-N,N,N'-(C.sub.1 -C.sub.4)alkyl substituted aminocarbonylamino, sulfonamido, (C.sub.1 -C.sub.4)alkylsulfonamido, amino, mono-N- or di-N,N-(C.sub.1 -C.sub.4)alkylamino, carbamoyl, mono-N- or di-N,N-(C.sub.1 -C.sub.4)alkylcarbamoyl, cyano, thiol, (C.sub.1 -C.sub.6)alkylthio, (C.sub.1 -C.sub.6)alkylsulfinyl, (C.sub.1 -C.sub.4)alkylsulfonyl or mono-N- or di-N,N-(C.sub.1 -C.sub.4)alkylaminosulfinyl; and V is a bond, thio(C.sub.1 -C.sub.4)alkylene, (C.sub.1 -C.sub.4)alkylenethio, (C.sub.1 -C.sub.4)alkyleneoxy, oxy(C.sub.1 -C.sub.4)alkylene or (C.sub.1 -C.sub.3)alkylene optionally mono- or di-substituted, when V is not a bond, independently with hydroxy or fluoro. 2. A compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein B is N; R is carboxyl, (C.sub.1 -C.sub.6)alkoxycarbonyl or tetrazolyl; Z is ethylenyl; R.sup.1 and R.sup.2 are each H; and L is n-propylenyl-X--. 3. A compound of claim 2, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein R.sup.5 is (C.sub.1 -C.sub.6)alkylsulfonyl or (C.sub.3 -C.sub.7)cycloalkylsulfonyl. 4. A compound of claim 2, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug, wherein R.sup.5 is G-sulfonyl and G is phenyl, imidazolyl, pyridyl, pyrazolyl or pyrimidyl optionally mono-, di- or tri-substituted on carbon or nitrogen with chloro, fluoro, methoxy, difluoromethoxy, trifluoromethoxy, trifluoromethyl or methyl. 5. A method of treating a vertebrate which presents with low bone mass comprising administering to said vertebrate a therapeutically effective amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug. 6. A method of claim 5 wherein osteoporosis, osteotomy, childhood idiopathic bone loss or bone loss associated with periodontitis is treated. 7. A method of claim 6 wherein osteoporosis is treated in a human. 8. A method of claim 7 wherein glucocorticoid-induced osteoporosis, hyperthyroidism-induced osteoporosis, immobilization-induced osteoporosis, heparin-induced osteoporosis or immunosuppressive-induced osteoporosis is treated. 9. A method for augmenting and maintaining bone mass in a vertebrate comprising administering to said vertebrate a therapeutically effective amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug. 10. A method of claim 9 wherein bone healing following facial reconstruction, maxillary reconstruction or mandibular reconstruction is treated, vertebral synostosis is induced or long bone extension is enhanced, the healing rate of a bone graft is enhanced or prosthetic ingrowth is enhanced. 11. A method of claim 9 wherein a bone fracture is treated in a human. 12. A method for treating a vertebrate having a condition which presents with low bone mass comprising administering to said vertebrate a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; and b. an amount of an anti-resorptive agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 13. A method of claim 12 wherein the anti-resorptive agent is droloxifene; raloxifene; tamoxifen; 4-hydroxy-tamoxifen; toremifene; centchroman; levormeloxifene; idoxifene; 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-o l; {4-[2-(2-aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiop hen-3-yl]-methanone; 3-(4-(1,2-diphenyl-but-1-enyl)-phenyl)-acrylic acid; 2-(4-methoxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thioph en-6-ol; cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetr ahydro-naphthalene-2-ol; (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro -naphthalene-2-ol; cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-nap hthalene-2-ol; cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahyd ronaphthalene; 1-(4'-pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrah ydroisoquinoline; cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetr ahydro-naphthalene-2-ol; or 1-(4'-pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoqui noline, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 14. A method of claim 13 wherein the anti-resorptive agent is tiludronic acid, zoledronic acid, alendronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 15. A method for treating a vertebrate which presents with low bone mass comprising administering to said vertebrate a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; and b. an amount of another bone anabolic agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 16. A method of claim 15 wherein said anabolic agent in component b is IGF-1, a bone morphogenetic protein (BMP), a prostaglandin, a prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), an active fragment of parathyroid hormone, a growth hormone or a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug. 17. A method for augmenting or maintaining bone mass in a vertebrate comprising administering to said vertebrate a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; and b. an amount of an anti-resorptive agent, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug. 18. A method of claim 17 wherein the anti-resorptive agent is droloxifene; raloxifene; tamoxifen; 4-hydroxy-tamoxifen; toremifene; centchroman; levormeloxifene; idoxifene; 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-o l; {4-[2-(2-aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiop hen-3-yl]-methanone; 3-(4-(1,2-diphenyl-but-1-enyl)-phenyl)-acrylic acid; 2-(4-methoxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thioph en-6-ol; cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetr ahydro-naphthalene-2-ol; (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro -naphthalene-2-ol; cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-nap hthalene-2-ol; cis-1-[6'-pyrrolodinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahyd ronaphthalene; 1-(4'-pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrah ydroisoquinoline; cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetr ahydro-naphthalene-2-ol; or 1-(4'-pyrrolidinolethoxyphenyl)-2-phenyl-6hydroxy-1,2,3,4-tetrahydroisoquin oline, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug. 19. A method of claim 17 wherein the anti-resorptive agent is tiludronic acid, zoledronic acid, alendronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 20. A method for augmenting and maintaining bone mass in a vertebrate comprising administering to said vertebrate a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; and b. an amount of a bone anabolic agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 21. A method of claim 20 wherein said anabolic agent in component b is IGF-1, a bone morphogenetic protein (BMP), a prostaglandin, a prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), an active fragment of parathyroid hormone, a growth hormone or a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug. 22. A pharmaceutical composition which comprises an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug and a pharmaceutically acceptable carrier or diluent. 23. A pharmaceutical composition of claim 22 for the treatment of osteoporosis wherein the amount is an osteoporosis treating amount. 24. A pharmaceutical composition of claim 22 for the augmentation of bone mass which comprises a bone mass augmenting amount of said compound, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug and a pharmaceutically acceptable carrier or diluent. 25. A pharmaceutical composition of claim 24 for the treatment of a bone fracture which comprises a bone fracture treating amount of said compound, prodrug thereof, or pharmaceutically acceptable salt of said compound or said prodrug. 26. A pharmaceutical composition of claim 22 for the treatment of a condition which presents with low bone mass in a mammal which comprises a low bone mass condition treating amount of said compound, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug and a pharmaceutically acceptable carrier or diluent. 27. A pharmaceutical composition comprising: a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug; b. an amount of an anti-resorptive agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug; and c. a pharmaceutical carrier or diluent. 28. A pharmaceutical composition of claim 27 wherein the anti-resorptive agent is droloxifene; raloxifene; tamoxifen; 4hydroxy-tamoxifen; toremifene; centchroman; levormeloxifene; idoxifene; 6-(4hydroxy-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-naphthalen-2-ol ; (4-(2-(2-aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy)-phenyl)-(6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiop hen-3-yl)-methanone; 3-(4-(1,2-diphenyl-but-1-enyl)-phenyl)-acrylic acid; 2-(4-methoxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thioph en-6-ol; cis-6-(4-fluoro-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetr ahydro-naphthalene-2-ol; (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydro -naphthalene-2-ol; cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydro-nap hthalene-2-ol; cis-1-(6'-pyrrolodinoethoxy-3'-pyridyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahyd ronaphthalene; 1-(4'-pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrah ydroisoquinoline; cis-6-(4-hydroxyphenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetr ahydro-naphthalene-2-ol; or 1-(4'-pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoqui noline, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 29. A pharmaceutical composition of claim 27 wherein the anti-resorptive agent is tiludronic acid, alendronic acid, zoledronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid or a pharmaceutically acceptable salt thereof. 30. A kit comprising: a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said salt in a first unit dosage form; b. an amount of an anti-resorptive agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug and a pharmaceutically acceptable carrier or diluent in a second unit dosage form; and c. container means for containing said first and second dosage forms. 31. A kit of claim 30 wherein the anti-resorptive agent is droloxifene; raloxifene; tamoxifen; 4-hydroxy-tamoxifen; toremifene; centchroman; levormeloxifene; idoxifene; 6-(4-hydroxy-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-naphthalen-2-o l; (4-(2-(2-aza-bicyclo[2.2. 1]hept-2-yl)-ethoxy)-phenyl)-(6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiop hen-3-yl)-methanone; 3-(4-(1,2-diphenyl-but-1-enyl)-phenyl)-acrylic acid; 2-(4-methoxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-benzo[b]thioph en-6-ol; cis-6-(4-fluoro-phenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetr ahydro-naphthalene-2-ol; (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydro -naphthalene-2-ol; cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydro-nap hthalene-2-ol; cis-1-(6'-pyrrolodinoethoxy-3'-pyridyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahyd ronaphthalene; 1-(4'-pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrah ydroisoquinoline; cis-6-(4-hydroxyphenyl)-5-(4-(2-piperidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetr ahydro-naphthalene-2-ol; or 1-(4'-pyrrolidinolethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoqui noline, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 32. A kit of 72 wherein the anti-resorptive agent is tiludronic acid, alendronic acid, zoledronic acid, ibandronic acid, risedronic acid, etidronic acid, clodronic acid, and pamidronic acid or a pharmaceutically acceptable salt thereof. 33. A pharmaceutical composition comprising: a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said drug; b. an amount of another bone anabolic agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug; and c. a pharmaceutical carrier or diluent. 34. The pharmaceutical composition of claim 33 wherein said bone anabolic agent in component b is IGF-1, a bone morphogenetic protein, prostaglandin, a prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), an active fragment or fragments of parathyroid hormone, a growth hormone or a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug. 35. A kit comprising: a. an amount of a compound of claim 1, a prodrug thereof or a pharmaceutically acceptable salt of said compound or said prodrug in a first unit dosage form; b. an amount of another anabolic agent, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug in a second unit dosage form; and c. container means for containing said first and second dosage forms. 36. A kit of claim 35 wherein said bone anabolic agent in component b is IGF-1, a bone morphogenetic protein, a prostaglandin, a prostaglandin agonist/antagonist, sodium fluoride, parathyroid hormone (PTH), an active fragment or fragments of parathyroid hormone, a growth hormone or a growth hormone secretagogue, a prodrug thereof or a pharmaceutically acceptable salt of said agent or said prodrug.

Details for Patent 6,376,502

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2017-10-10